Filing Flows › 8-K events › Zevia PBC
Zevia PBC: entry into a material definitive agreement
Form 8-K filed Oct 23, 2026 · items 1.01, 3.02, 3.03, 5.03, 7.01
Share offeringsZevia Announces $20 Million Growth Equity Investment
What the filing says
On October 22, 2026 (the “Effective Date”), Zevia PBC (“Zevia” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Bubble Holdings, LLC, a Delaware limited liability company and an affiliate of GP Investments, Ltd. (the “Purchaser”). Pursuant to the Purchase Agreement, on the
ScaleThe filing names $20.0M: about 10% of Zevia PBC's annual revenue ($193.4M, four times the latest quarter).
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 3.02: +0.1% next session across 2,750. Item 3.03: +0.1% next session across 1,456. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Zevia PBC at a glance
Zevia PBC, Q3 2026: revenue $48.3M (+18% year over year), operating margin -4.5%. The chart follows the revenue to costs, profit and cash.
Zevia PBC: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent share offerings
- Airsculpt Technologies Nov 6, 2026
- Biovie Nov 6, 2026
- Clean Energy Technologies Nov 6, 2026
- Nextnrg Nov 6, 2026
- Paid Nov 6, 2026
- Silo Pharma Nov 6, 2026
- Agility Robotics Nov 6, 2026
- American Healthcare REIT Nov 6, 2026
- Entera Bio Nov 6, 2026
- Janus Living Nov 6, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.